Table 1 |
|
|
Target product profile of developed ASAQ formulation |
|
|
Attribute |
Target product characteristics |
|
|
|
|
API |
AS and AQ |
|
|
|
|
Population targeted |
pediatric and adult |
|
|
|
|
Posology |
based on [7] ASAQ low strength 25/67.5 mg (equivalent AQ base) for children ASAQ high strength 100/270 mg (equivalent AQ base) for older children and adults |
|
|
|
|
Drug release |
rapid disintegration and fast drug release (> 75% in 45 minutes in vitro dissolution test, Pharmacopoeia standards) |
|
|
|
|
Drug form |
compatible with pediatric use: minimal size for facilitating swallowing; a fixed dose combination |
|
|
|
|
Stability/Conditioning |
compatible with climatic zone IV (tropical conditions): ICH Q1A(R2) |
|
|
|
|
Cost |
< 1$ |
|
|
|
|
Lacaze et al. Malaria Journal 2011 10:142 doi:10.1186/1475-2875-10-142 |
|
